Syndax Pharmaceuticals, Inc. Paid-in-Kind Interest
Syndax Pharmaceuticals, Inc. (SNDX) reported Paid-in-Kind Interest of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2023-11-02
- Syndax Pharmaceuticals, Inc. paid-in-kind interest for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. paid-in-kind interest for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. paid-in-kind interest for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. paid-in-kind interest for the quarter ending 2022-09-30 was $792.00K, a 538.71% increase year-over-year.
- Syndax Pharmaceuticals, Inc. paid-in-kind interest for fiscal 2020 was $389.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | |||
| 2022-09-30 | $792.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $951.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.10M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $311.00K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $152.00K 10-Q · filed 2023-05-08 | |||
| 2021-09-30 | $124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $244.00K derived: sum of 2 quarters · filed 2022-11-03 | $358.00K 10-Q · filed 2022-11-03 | $471.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $234.00K 10-Q · filed 2022-08-08 | $347.00K derived: sum of 3 quarters · filed 2022-08-08 | $457.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $114.00K 10-Q · filed 2022-05-09 | $227.00K derived: sum of 2 quarters · filed 2022-05-09 | $337.00K derived: sum of 3 quarters · filed 2022-05-09 | $441.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $223.00K derived: sum of 2 quarters · filed 2021-11-15 | $327.00K derived: sum of 3 quarters · filed 2021-11-15 | $389.00K 10-K · filed 2021-03-12 |
| 2020-09-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $214.00K derived: sum of 2 quarters · filed 2021-11-15 | $276.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $166.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $62.00K 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |